focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 11,850.00
Ask: 12,400.00
Change: 0.00 (0.00%)
Spread: 550.00 (4.641%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Brazil to seek regulatory approval for AstraZeneca vaccine on Jan. 15

Mon, 28th Dec 2020 21:18

(Adds comments by health official and Bolsonaro, background,
details)

By Pedro Fonseca

RIO DE JANEIRO, Dec 28 (Reuters) - Brazil's Fiocruz
biomedical institute will seek approval for the Oxford
University/AstraZeneca vaccine against COVID-19 with
federal health regulator Anvisa on Jan. 15, one of the center's
senior officials said on Monday.

The Jan. 15 date brings a measure of clarity to Brazil's
vaccine rollout, which critics have blasted for falling behind
smaller and poorer peers in Latin America. The AstraZeneca
vaccine represents the Brazilian government's main bet to help
end the world's second-most deadly coronavirus outbreak, after
the United States.

"The final submission of this process, this last milestone,
will be on Jan. 15," Marco Krieger, vice president of health
production and innovation at the Rio de Janeiro-based Fiocruz
institute, told Reuters.

Once seen as a front-runner in the development of a
coronavirus vaccine, the British team has been overtaken by U.S.
drugmaker Pfizer Inc and partner BioNTech,
whose shots are already being used in Britain and the United
States.

Confusion has arisen over the best dosage. Data published
earlier from the British team's Phase 3 trials showed efficacy
was 62% for trial participants given two full doses, but a more
robust 90% for a sub-group given first a half, then a full dose.

Krieger said Fiocruz would apply to Anvisa with a two-dose
regimen, which, despite being less effective, was more widely
tested, including in Brazil.

He said Fiocruz would be applying for a full approval with
Anvisa, rather than an emergency use application. Pfizer, which
is in talks to sell its vaccine to Brazil's federal government,
has said the emergency use application is onerous.

Krieger said the institute would start filling and finishing
1 million doses per week in January, then ramp up to 3 million
weekly doses in early February.

Fiocruz is licensed to receive supplies from AstraZeneca and
eventually produce the vaccine locally. Brazil's federal
government, which has ordered the AstraZeneca vaccine, expects
to receive 100 million doses in the first half of 2021.

Brazilian President Jair Bolsonaro, one of the world's most
prominent coronavirus skeptics, said over the weekend he was not
worried about criticism over the speed of Brazil's vaccine
rollout, saying he felt no pressure.

"Nobody pressures me for anything, I don't give a damn about
it," he said in a video aired on CNN Brasil.

Bolsonaro, who caught the virus in July, has also said he
will not take any COVID-19 vaccine, adding to growing vaccine
skepticism in Brazil.

Brazil now has nearly 7.5 million confirmed cases, and
191,139 deaths from the virus since the outbreak began,
according to data from the Health Ministry.
(Reporting by Pedro Fonseca in Rio de Janeiro
Writing by Gabriel Stargardter
Editing by Brad Haynes and Matthew Lewis)

More News
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.